Molecular features evaluation of metastatic foci as the basis for metastatic breast cancer treatment personalization. Is there a place of CDK4/6-inhibitors in late-line therapy after chemotherapeutic regimens?
The problem of metastatic breast cancer treatment is linked with clonal selection both in the process of tumor evolution and under the influence of previous treatment. The analysis of metastatic niche microenvironment and the molecular genetic features become essential for treatment individuali...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/6580 |